Following a manufacturing mistake that left Emergent BioSolutions with a botched batch of Johnson & Johnson’s Covid-19 vaccine, the company is facing a shareholder lawsuit accusing it of insider trading.
https://www.pharmalive.com/wp-content/uploads/2021/07/Emergent-Under-Fire-for-Insider-Trading-in-Shareholder-Lawsuits-BioSpace-7-7-21.jpeg350625Andrew Humphreyshttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngAndrew Humphreys2021-07-07 20:47:052021-07-08 00:04:28Emergent Under Fire for Insider Trading in Shareholder Lawsuits